BioCryst Pharmaceuticals | BCRX - Umsatzerlöse





Der Umsatz Veränderung Datum
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Chugai Pharma JPY 346.3B 13.12B 2025-12
Daiichi Sankyo JPY 558.11B 57.35B 2025-12
DBV Technologies USD 2.77M 1.31M 2025-09
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novavax USD 147.14M 76.69M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12